Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Danja Grossbach

Michael Sander

Britta Olenik

Heiko Schirmer

Peter Serno

Donald Bierer

Kai Lovis

Philipp Rubenbauer

Gabriele Winter

Wolfgang Beckmann

Julia Küsel

Christian Dinter

Anke Stroyer

Tia Jacobs

Tilo Haag

Klaus Bartel

Carmen Lobback

Franz-Josef Mais

William J Guilford

Andreas Lender

Maurus Marty

Juergen Stiehl

Jan-Georg Peters

Martin Seyfried

Theodor Zweifel

Daniel Gotz

Gunter Weingartner

The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.

Orally administrable modified-release pharmaceutical dosage form

This invention is directed to the crystalline potassium salt of a lipoxin Aanalog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.

[object Object]

This invention is directed to compounds useful as intermediates in the synthesis of lipoxin Aanalogs of the following formulas (I) and (II): wherein R, R, R, Rand Rare described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.

Crystalline potassium salt of lipoxin A4 analogs

Growing community of inventors

Berlin, Germany

Danja Grossbach